Eli Lilly Responds to Allegations It Hid Zyprexa Diabetes Data

INDIANAPOLIS - Drug Maker Eli Lilly has responded to allegations that its sales representatives were instructed by the company to downplay the risk of diabetes associated with its schizophrenia drug, Zyprexa.

Lilly issued a press release Dec. 18 in response to a New York Times article that said internal company documents show that Lilly executives hid important data about the link between diabetes and Zyprexa from doctors who prescribed the drug.

The Indianapolis-based pharmaceutical company called the release of documents to the newspaper 'illegal' and denied that it engaged in off-label promotion of Zyprexa or that the information provided to …